Trial Profile
An open, Randomized, Multi-centered Phase III study on the efficacy and safety of CreaVax-RCC Inj. (Autologous Mature Dendritic Cells) versus Sorafenib tosylate in patients with metastatic renal cell carcinoma.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-CreaGene (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors JW CreaGene
- 13 Sep 2011 New trial record